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Aim: To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society.
Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who
were diagnosed in 2010 met the study criteria. The inclusion criteria included patients whose diagnosis was confirmed with a biopsy,
with the presence of adequate pathologic material for review, between the ages of 40 and 80, and who were healthy men without a family
history of prostate cancer. The exclusion criteria excluded men diagnosed with another cancer and those who had kin with a history of
prostate cancer. A direct DNA sequencing method was utilized for detection of polymorphisms.
Results: CAG repeat length varied from 13 to 28 (mean: 21.67) for the BPH group and 12 to 28 (mean: 21.74) for the prostate cancer
group. Prostate-specific antigen (PSA) density and the androgen receptor (AR) CAG repeat had a statistically significant negative
correlation in the BPH group. A statistically significant difference was associated between AR CAG repeat and PSA density.
Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which
may open new horizons in prostate cancer screening and early detection.
Key words: Androgen receptor, mutation, polymorphism, prostatic hyperplasia, prostatic neoplasm

1. Introduction
Prostate cancer is the most common type of cancer in
men in all countries of the world and ranks third among
the causes of death resulting from cancer, after lung and
colon cancers. This difference is due to known genetic and
environmental factors (1,2).
Androgen receptors (ARs), by initiating the
transcription of genes responsible for androgen, will add to
the activity of testosterone and dihydrotestosterone. The AR
gene includes 2 polymorphisms involved in the initiation
and progression of prostate cancer. Exon 1 contains the 2
polymorphic trinucleotide repeat encoding polyglutamine
(CAG)n (3). Polymorphic repeat length is inversely related
to the AR gene transcription activity (e.g., it regulates
androgen receptors’ response to androgens) (4).
Short CAG repeat lengths have been proposed as
increasing the androgen activity organized by AR,
leading to increased sensitivity to prostate cancer and
benign prostatic hyperplasia. In line with this hypothesis,
numerous epidemiological studies found an association
between the CAG repeat length and prostate cancer risk
* Correspondence: drkizilay@hotmail.com

and cancer aggressiveness (5). In men with CAG repeat
lengths of less than 18, as compared to those with repeats
of longer than 26, the relative risk (RR) of prostate cancer
was found to be more than 1.5-fold. Shorter CAG lengths
are associated with advanced stage (RR: 2.2) and highgrade disease (RR: 1.9) (6,7).
In studies of men without prostate cancer, short CAG
repeat length prevalence was found to be highest in
African-Americans, moderate in non-Hispanic whites,
and lowest in Asians (6). These data suggest that ethnic
differences in the incidence of prostate cancer may be
partly explained by AR polymorphism.
In this prospective study, we aimed to evaluate the
relationship between AR gene polymorphism and prostate
cancer in our society. The detection of AR gene variants
may play an important role in the early diagnosis and
treatment of prostate cancer, and could help relate it to the
clinical phenotype and provide the genotype–phenotype
correlation. Our main goal was to make use of them as
prognostic indicators.
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2. Materials and methods
Thirty-nine patients diagnosed with prostate cancer
(PCa) and 34 patients diagnosed with benign prostate
hyperplasia (BPH) were included in this single-center,
multidisciplinary, prospective study. Volunteers in both
groups were between 40 and 80 years old and the diagnoses
(PCa and BPH) were confirmed by biopsy.
Prostate-specific antigen (PSA) was measured as
ng/mL. The volume of the prostate was calculated by
transrectal ultrasound (TRUS), and for the fraction of
patients who had not received TRUS, it was calculated as
an average by digital rectal examination.
Direct DNA sequencing is a commonly used method
for the detection of CAG repeat expansion in the first exon
of the AR gene (5). We also benefited from this method.
After obtaining approval from the ethics committee, all
patients who participated in this study filled in a consent
form. A 1-mL blood sample was taken from all individuals
who agreed to participate in the study and placed into
tubes containing ethylenediaminetetraacetic acid to
obtain genomic DNA for analysis of AR gene CAG repeat
mutations.
2.1. Genomic DNA extraction
Extraction of total genomic DNA from peripheral blood
leukocytes was performed with the unsalted column
purification method. A QIAGEN Mini Blood DNA
Isolation Kit was used for this purpose. For measuring the
purity of DNA, the DNA solution absorbance intensity
was measured with a NanoDrop Spectrophotometer
device at a wavelength of 280 nm. DNA quality level was
determined by electrophoresis of 2 µL (100 ng) of DNA in
1% agarose gel.
Genotyping analysis of the AR gene polymorphisms
were performed by polymerase chain reaction (PCR)
followed by a DNA sequencing analysis method. First, the
AR gene PCR amplification reactions were performed.
For this purpose, a mixture of 100 ng of genomic
DNA, 1X PCR buffer (10 mM Tris–HCl, 50 mM KCl, pH
8.3), 1.5 mM MgCl 2 (Applied Biosystems), 200 mM each
of deoxynucleotide triphosphates (dNTPs) (Promega,
Madison, WI, USA), 1 µM sense and 1 µM antisense
primers (Invitrogen Ltd., Paisley, UK), and 1 U AmpliTaq
Gold DNA Polymerase (Applied Biosystems, Foster City,
CA, USA) was completed to 25 µL with deionized water
and subjected first to a total of 10 min denaturation at 94
°C followed by 35 cycles at an annealing temperature of 60
°C, and PCR was completed at 72 °C for 10 min and then
at 4 °C (endless process). The obtained PCR amplification
products were checked by agarose gel electrophoresis.
Before cycle sequencing reactions, the amplified PCR
products were purified using an Exo-SAP PCR purification
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kit (Amersham Life Science). Cycle sequencing PCR
was performed using a BigDye Terminator v.3.1 kit as
per manufacturer’s instructions (Applied Biosystems).
Cycle sequencing PCR products, after purification with
a BigDyeXT Terminator kit (Applied Biosystems), were
analyzed using an ABI 3130xl genetic analyzer system.
DNA sequencing was performed in both directions,
initiated from the forward and the reverse primers used
in the initial PCR reaction (Figures 1 and 2). For sequence
evaluation, the SeqScape 2.0 sequencing analysis software
was used.
2.2. Statistical analysis
All data were prospectively collected. Descriptive statistics,
Student’s t-test, and Pearson’s correlation analyses were
performed. Significance was defined as P < 0.05.
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Figure 1. DNA sequence electropherogram for CAG repeats of
(28 repeats) AR gene exon 1.
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Figure 2. DNA sequence electropherogram for CAG repeats of
(11 repeats) AR gene exon 1.
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3. Results
A total of 73 patients, with 39 prostate cancer and 34 BPH
patients, were enrolled in the study. All patients were
diagnosed in 2010. Age, PSA, prostate volume, PSA density
(PSA value to prostate volume ratio), and the number of
AR CAG repeats were compared between the 2 groups.
The Gleason score and the family history of prostate
cancer were also evaluated in the prostate cancer group.
While the average age of diagnosis for the BPH group was
69.45 years, it was 63.90 for the cancer group. While PSA
varied between 0.2 ng/mL and 27.7 ng/mL (mean: 3.282
ng/mL) for the BPH group, it varied between 0.015 ng/
mL and 101.9 ng/mL (mean: 9.510 ng/mL) for the cancer
group (Figure 3).
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Figure 3. PSA comparison between groups.

While prostate volume varied from 21 mL to 52 mL
(mean: 32.42 mL) for the BPH group, it varied between
21 mL and 75 mL (mean: 41.21 mL) for the cancer group.
While PSA density varied from 0.005 to 0.630 (mean:
0.093) for the BPH group, it varied between 0.001 and
1.644 (mean: 0.208) for the cancer group.
CAG repeat length varied from 13 to 28 (mean: 21.67)
for the BPH group and varied between 12 and 28 (mean:
21.74) for the prostate cancer group (Figure 4).
PSA density and the androgen receptor CAG repeat
length had a statistically significant negative correlation in
the BPH group (Spearman’s rho = –0484, P = 0.004).
The androgen receptor CAG repeat length in the cancer
group was negatively correlated with the Gleason score,
but was not statistically significant (Spearman’s rho =
–0.049, P = 0.765). A statistically significant difference was
associated between androgen receptor CAG repeat length
and PSA density (Spearman’s rho = 0321, P = 0.046).
While in the group with family history of prostate cancer
the average age at diagnosis was 65.46 years, it was 63.12
for the patients without a family history. PSA density was
0.170 in the group with a family history, and it was 1.227 in
the group without a family history. CAG repeat length was
22.15 in the group with a family history, while it was 21.54
for the patients without a family history (Figure 5).
A positive correlation was determined between PSA
and AR CAG repeat length, although it was not statistically
significant (Spearman’s rho = 0207, P = 0.206).
4. Discussion
Prostate cancer is the fourth most common male
malignancy in the world. Incidence and mortality rates
vary greatly among countries. This variability is very
similar to changes, as observed in the United States,

Figure 4. CAG repeat length comparison between the groups.
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Figure 5. Comparison between family history with age of diagnosis and CAG repeat length.

between different ethnic groups. In the United States
prostate cancer is the second most common cause of
cancer diagnosis and cancer-related deaths among males.
Incidence and mortality rates are generally higher in
Western countries than developing countries. Since the
beginning of 1990, new screening tests and treatment
improvements have led to a dramatic amelioration in the
incidence, mortality, and diagnostic phase of this disease.
Huge advances in molecular biology and epidemiology
have opened new horizons in the etiology and biology of
prostate cancer. These developments will lead to a better
understanding of this disease and will open new and better
ways for the prevention and treatment of prostate cancer
in the foreseeable future.
Many authors are in consensus about the fact that
aggressive screening and treatment is responsible for the
decrease in prostate cancer mortality. This result seems
especially plausible considering that prostate cancer
mortality rates have not decreased in the countries where
the PSA test has not yet begun to be used as routine. The
role of PSA has been clearer as a result of prostate, lung,
colon, rectum, and ovarian cancer screening trials as the
scan reached a certain maturity.
The etiopathogenesis of prostate cancer is largely
unknown, but the available data suggest that the disease
is multifactorial (8). Androgens are the main male sex
hormones and manage male secondary differentiation,
spermatogenesis, and development of the accessory sex
organs, including the prostate gland. Androgens act through
the AR protein, which is a ligand-dependent nuclear
transcription factor. The role of androgens in prostate
cancer has not been fully elucidated yet. If the AR has
oncogenic potential, androgen may play a role in initiating
prostate cancer. The AR gene is mapped on the long arm of
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the X chromosome (Xq11.2-q12). The N-terminal region
of AR gene first exon is highly polymorphic, containing
a variable number of CAG and GGC repetitions and
codes for polyglutamine and polyglycine tracts (9). Age
is the most important risk factor for PCa and BPH in all
populations studied. There are studies indicating that a
short CAG repeat length constitutes an increased risk for
PCa and BPH (10), while a similar number of studies state
that there is no relation between the repeat length and PCa
risk (11). However, increasing CAG repeats have been
associated with androgen insensitivity, testicular atrophy,
and infertility (12). Experimental studies found an
inverse relationship between the transactivation activity
of the receptor and CAG repeat numbers (8). A typical
distribution of the CAG repeats varies between 11 and 31
(13). It is shorter in African-Americans (20 repeats) than
whites (22 repeats) (13). Many, but not all, epidemiological
studies emphasized that shorter androgen receptor gene
CAG repeat numbers were related to a higher risk of
prostate cancer (13,14).
Prostate cancer risk may be inversely related to the
number of CAG repeats. Coetzee and Ross suggested that
the variations of CAG repeat length were associated with
prostate cancer risk (15). Accordingly, most description
are concerned with short alleles with polyglutamine tract
glutamine residues on the receptor, which can do more high
transactivation, depending on the inverse relationship with
transcriptional activity (15). This potential relationship can
be modified with the stage/degree at diagnosis (16) and
the men who were diagnosed at more advanced ages seem
to have longer CAG repeats (17), while 2 studies found no
statistically significant relationship between short CAG
length and formation of prostate cancer (18,19). Bratt et
al. (11) determined the relationship between CAG repeats
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and diagnosis at a young age, but did not find a relationship
with high risk. Eeles et al. (12) found no correlation
between CAG repeat number and cancer development
and aggressiveness in their study consisting of 178 cases
of Caucasian patients and controls. To date, many studies
have reported a positive association between short CAG
repeat numbers and prostate cancer. On the other hand,
the potential importance of the relationship is relatively
limited, because of the limited sensitivity of the published
results due to their small case groups.
With regard to the severity of prostate cancer,
Giovannucci et al. (5) identified an inverse relationship
between CAG repeat number and grade/degree. Stanford
et al. (7) found that shorter repeats involve a higher risk for
disease severity compared with longer ones. These results
demonstrated that short repeats are not only associated
with the development of cancer but are also associated
with the potential severity of the cancer.
Decreased repeat length may make the prostate more
vulnerable to chronic androgen stimulation and may
result in an increase in consequent proliferative activity
and somatic mutation rate (20). AR repeat polymorphisms
have been associated in the incidence of other androgendependent clinical conditions, such as a high number of
repetitions adversely affecting fertility, spermatogenesis,
and bone density. A low number of repeats is associated
with an increased risk of baldness and, occasionally, BPH
(21).
Fewer studies have reported about the AR CAG repeat
and BPH connection than the connection with cancer. No
association between CAG repeat polymorphism and the
risk of BPH was found in a population in the Netherlands
(22).
Prostate cancer incidence and mortality differences
among blacks, whites, and Asians may be explained by
nutritional and socioeconomic factors, but to fully explain
this difference, genetic components are required. Short
CAG repeats are associated with high histologic grade,
extracapsular extension, and a metastatic phenotype
explained as an aggressive prostate cancer; however, this
connection is controversial. Giovannucci et al. (5) found
that the patients with the shortest length of CAG repeats
have the most risk of cancer, while some studies could not
determine any connection between the number of CAG
repeats and tumor grade, stage at diagnosis, and PSA value
(20).
For our study, CAG repeat length for the BPH group
ranged between 13 and 28 (mean: 21.67), while it ranged
between 12 and 28 (mean: 21.74) for the prostate cancer
group. The number of repetitions for the prostate cancer

group was a little higher, although the difference was not
statistically significant.
We detected a statistically significant negative
correlation between PSA density and androgen receptor
CAG repeats in the BPH group. The literature includes
a limited number of studies on the relationship between
BPH and the number of CAG repeats. While no association
was found between the CAG repeat polymorphism and
the risk of BPH among the population of the Netherlands,
in the Finnish population short CAG repeats were rare in
patients with BPH, similar to our study (17,22).
The androgen receptor CAG repeat length was
negatively correlated with the Gleason score in the cancer
group, but that was not statistically significant. This result
lends support to the theory that a shorter CAG repeat
sequence is associated with extraprostatic extension,
distant metastasis, or high degree, as mentioned previously
by Lai et al. (20). The relationship between androgen
receptor CAG repeats and PSA density was found to be
statistically significant. A positive correlation was found
between PSA and androgen receptor CAG repeat length,
although it was not statistically significant. Two studies
in the literature found no connection between the PSA
value and the number of CAG repeats (23,24). While PSA
density was 0.170 in patients with a positive family history,
it was 0.227 in the group without history. The CAG repeat
length was 22.15 in the group with a positive history and
was 21.54 in the group without history. Positive correlation
was obtained between PSA and androgen receptor CAG
repeat length, although it was not statistically significant.
Our study, examining the link between the number of
CAG repeats and prostate cancer risk and other factors,
is the first for Turkish society. By increasing the number
of patients, and with the addition of other parameters,
especially serum testosterone levels, different correlations
can be analyzed and the meaning and importance of
CAG repeat number in prostate cancer for the Turkish
population can be assessed in more detail. As outlined,
an evidence-based CAG repeat length test in the general
population has not been verified yet. These results have
shown that there is a need for additional studies on this
subject. The relationship between AR CAG repeats and
prostate cancer is interesting, but is limited to some extent.
For a better understanding of prostate carcinogenesis
we have to fully explain the relationship between genes
associated with CAG repeats and environmental factors
that increase the risk of prostate cancer. As a result, our
ability to prevent prostate cancer will increase and it will
provide more useful information in new diagnoses.
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